Skip to main content
Dermatology and Therapy logoLink to Dermatology and Therapy
. 2024 Jan 20;14(1):183–185. doi: 10.1007/s13555-023-01076-x

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Kim Rand 1,, Juan Manuel Ramos-Goñi 1, Bülent Akmaz 2, Laia Solé-Feu 3, José-Carlos Armario-Hita 4
PMCID: PMC10828252  PMID: 38245639

Correction to: Dermatol Ther (Heidelb) 10.1007/s13555-023-01058-z

Authors would like to correct the Error in Fig. 1, which should illustrate that the study arms were compared in the study. As reflected in the text, these are the Q2W arm from the SOLO-CONTINUE study and the Q4W arms from the ADvocate trial. However, the gold border for the ADvocate trials is erroneously placed around the Q2W arms. The revised version of Fig. 1 is updated here.

graphic file with name 13555_2023_1076_Fig1_HTML.jpg

ADvocate and SOLO-CONTINUE trial designs. The arms used in this study are outlined in gold

The revised version of Table 1 is updated here.

Table 1.

SOLO-CONTINUE and corresponding ADvocate aggregate data

Variable SOLO-CONTINUE
Dupilumab QW/Q2W
ADvocates 1 & 2
N (%) 169 (100%) 101 (100%)
Age, mean (SD) 38.5 (13.94) 39.4 (16.1)
Proportion male, n (%) 82 (48.5%) 45 (44.6%)
Race
 White, n (%) 124 (73.4%) 75 (74.3%)
 Asian, n(%) 31 (18.3%) 14 (13.9%)
 Other, n(%) 14 (8.3%) 12 (11.9%)
Baseline scores (maintenance baseline, week 16 of treatment)
EASI, mean (SD) 2.6 (2.92) 2.4 (2.5)
EASI-75, n (%) 162 (95.9%) 101 (100%)
IGA, mean (SD) 1.15 (0.61) 1.2 (0.85)
IGA 0/1, n (%) 129 (76.3%) 63 (62.4%)
DLQI, mean (SD) 3.4 (4.21) 3.5 (3.47)
POEM, mean (SD) 6.4 (5.3) 7.7 (5.3)
% BSA, mean (SD) 7.9 (9.02) 5.9 (7.23)
End-of-study scores (week 52 of treatment)
IGA 0/1, n (%) 68 (40.2%) 56 (55.4%)
EASI-75, n (%) 116 (68.6%) 69 (68.3%)
Overall AE, n (%) 118 (69.8%) 74 (73.3%)

Bold italics for variables used in propensity score weighting

SD: Standard Deviation; QW/Q2W: weekly or bi-weekly administration; EASI: Eczema Area and Severity Index; IGA: Investigator Global Assessment; DLQI: Dermatology Life Quality Index; POEM: Patient Oriented Eczema Measure; BSA: Body Surface Area; IGA 0/1: IGA score of 0 or 1, clear/almost clear skin; EASI-75: 75% improvement in EASI score from baseline; AE: Adverse Events

Affiliation of authors Kim Rand and Juan Manuel Ramos-Gon updated from ‘Health B.V’ to ‘Maths in Health B.V’.

The original article has been corrected.


Articles from Dermatology and Therapy are provided here courtesy of Springer

RESOURCES